Analytical Data
-
基因名
C1qA
- Application
-
别名
C1qA；Complement C1q subcomponent subunit A
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P02745
-
表达区间
23-245aa
-
氨基酸序列
EDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIRTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAIRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSRGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFLIFPSA
-
分子量
30.7 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
C1qA, a crucial component of the complement system, plays a significant role in innate immunity as it initiates the classical pathway for complement activation. The complement system is vital for immune surveillance, promoting opsonization, inflammation, and cell lysis, thereby aiding in pathogen clearance and maintaining homeostasis. Research has increasingly focused on C1qA due to its involvement not only in immune response but also in various pathological conditions, including autoimmune diseases and neurodegenerative disorders. Understanding the structure-function relationship of C1qA can elucidate its mechanisms and regulatory roles in immunity. Recombinant C1qA proteins have been developed to study these properties in vitro and in vivo, offering potential therapeutic applications for diseases characterized by complement dysregulation. The advancement of recombinant DNA technology facilitates the production of C1qA with specific modifications, enabling detailed exploration of its functional domains and interactions with other complement components and immune cells. This research not only enhances the understanding of complement biology but also opens avenues for novel treatment strategies targeting complement-mediated diseases.
